Word leaked out late last week of China's rejection of a patent application by Gilead Sciences Inc. related to the blockbuster hepatitis C virus (HCV) drug, Sovaldi (sofosbuvir), putting a damper – at least for now – on the company's scheme to introduce one of its top-selling drugs into the world's most populous country.